Michael S. Iskra - May 27, 2022 Form 4 Insider Report for Ortho Clinical Diagnostics Holdings plc (OCDX)

Role: Executive Vice President
Signature: /s/ Michael A. Schlesinger, Attorney-in-Fact
Stock symbol: OCDX
Transactions as of: May 27, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/1/2022, 04:16 PM
Previous filing: May 25, 2021
Next filing: Jun 3, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OCDX	Ordinary Shares, $0.00001 par value	Disposed to Issuer		-150K	-100%		0	May 27, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	OCDX	Stock Option	Disposed to Issuer		-209K	-100%		0	May 27, 2022	Ordinary Shares, $0.00001 par value	209K	$6.28	Direct	F3
transaction	OCDX	Stock Option	Disposed to Issuer		-239K	-100%		0	May 27, 2022	Ordinary Shares, $0.00001 par value	239K	$12.56	Direct	F3
transaction	OCDX	Stock Option	Disposed to Issuer		-79.7K	-100%		0	May 27, 2022	Ordinary Shares, $0.00001 par value	79.7K	$12.56	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Michael S. Iskra is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Reflects restricted stock units.
F2	Pursuant to the Business Combination Agreement, dated December 22, 2021 (the "BCA"), by and among Coronado Topco, Inc. ("Coronado Topco"), Laguna Merger Sub, Inc., Orca Holdco, Inc., Orca Holdco 2, Inc., Quidel Corporation and the Issuer, the Issuer became a wholly owned subsidiary of Coronado Topco upon consummation of the business combinations (the "Effective Time"). At the Effective Time: (a) each of the Issuer's ordinary shares was automatically converted into the right to receive (i) 0.1055 shares of common stock of Coronado Topco and (ii) $7.14 in cash; and (b) each restricted stock unit, whether vested or unvested, was converted into a Coronado Topco equity right of the same type and on the same terms and conditions as were applicable to the corresponding restricted stock unit immediately prior to the Effective Time, which right shall be settled in cash upon vesting.
F3	At the Effective Time, each stock option, whether vested or unvested, was converted into (a) a Coronado Topco stock option on the same terms and conditions as were applicable to such stock option immediately prior to the Effective Time, except as adjusted by the BCA, (b) with respect to the portion of such stock option that is vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the vested portion of such stock option and (c) with respect to the portion of such stock option that is not vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the unvested portion of such stock option when it vests in accordance with its terms.